Dr. Alissa Sue Marr, MD

Dr. Marr practices at Nebraska Medical Center in Omaha, Nebraska, part of University of Nebraska System.

Dr. Marr's NPI, 1376624924, was assigned on October 18, 2006. Dr. Marr graduated from University of Nebraska College of Medicine in 2003. Dr. Marr holds Nebraska license 23749.

Dr. Marr's primary practice is Nebraska Medical Center, at 988102 Nebrasks Medical Center, Omaha, NE 68198 in Douglas County. The practice phone is (402) 559-4000. Dr. Marr also practices at Nebraska Medical Center, 987400 Nebraska Medical Ctr, Omaha, NE 68198.

Dr. Marr's primary practice is Nebraska Medical Center in Omaha, Nebraska, part of University of Nebraska System. Dr. Marr is also affiliated with Bellevue Medical Center. The medical group on file is UNMC Physicians. Dmand AI also links Dr. Marr to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Marr practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Marr's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Marr is licensed in Nebraska.

CMS data shows 390 Medicare services from Dr. Marr across 6 procedure codes in 2024, for 171 Medicare patients. Medicare paid $28,764 for them.

CMS counts 171 Medicare patients who saw Dr. Marr in 2024. The largest group is 65 to 74, with 92 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.12, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Marr's median patient age at 73, with 44% women.

In 2024, Dr. Marr wrote 230 Medicare Part D claims for 36 patients. 58% of them were for generic drugs. CMS names the drug for 143 of them, across 8 drugs with 11 or more claims each, at $1,156,197 in total drug cost. In 2023, CMS named 118 claims across 7 drugs.

Dr. Marr accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Marr as offering telehealth.

Dmand AI links 27 papers to Dr. Marr, published from 2015 to 2024. 2023 was the busiest year, with 5. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Marr has published most often in J Thorac Dis. Dr. Marr's most frequent co-authors are Richard L. Schilsky, MD, Ramya Thota, MBBS and Deepti Behl, MD.

Dmand AI links Dr. Marr to 5 clinical trials, 2 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Carcinoma, Basosquamous, Carcinoma, Non-Small-Cell Lung and Carcinoma, Transitional Cell. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 21 general payments to Dr. Marr from 10 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Delcath Systems paid the most, $137.

Dr. Marr graduated from University of Nebraska College of Medicine in 2003.